Trials / Completed
CompletedNCT05918796
Comparison Between Bupivacaine and Bupivacaine- Dexamethasone QLB for Postoperative Analgesia
Ultrasound-guided Quadratus Lumborum Block Using Bupivacaine Versus Bupivacaine - Dexamethasone as Postoperative Analgesia in Laparoscopic Cholecystectomy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the analgesic sparing effect of adding Dexamethasone to Bupivacaine in Quadratus lumborum block in patients undergoing Laparoscopic cholecystectomy under general anesthesia.
Detailed description
Background: The QLB is an effective analgesic technique for various abdominal wall incisions. The QLB covers T7 to L2 dermatomes by the spread of LA drugs either into the paravertebral space or in the thoracolumbar plane, through iliohypogastric and ilioinguinal nerves, A and C fiber nociceptors, mechanoreceptors and high-density network of lumbar sympathetic fibers. Objective: To assess the analgesic sparing effect of adding Dexamethasone to Bupivacaine in Quadratus lumborum block in patients undergoing Laparoscopic cholecystectomy under general anesthesia. Patients and Methods: Sixty patients scheduled for elective Laparoscopic cholecystectomy surgeries under general anesthesia were included in this study, they were divided into two groups. Group A (perineural dexamethasone and bupivacaine group) \[n=30\] Those cases will receive 2ml volume of dexamethasone (8mg) combined with 18 ml of bupivacaine of 0.25% concentration. Group B (perineural bupivacaine group) \[n=30\] Those cases will receive perineural 18 ml bupivacaine (0.25%) combined with 2 ml normal saline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivacaine | 18 ml of bupivacaine of 0.25% injected bilaterally in quadratus lumborum block |
| DRUG | Dexamethasone | dexamethasone |
Timeline
- Start date
- 2023-06-15
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2023-06-26
- Last updated
- 2023-08-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05918796. Inclusion in this directory is not an endorsement.